NewslettersProstate Cell NewsPulmonary Cell NewsSplice-Switching Antisense Oligonucleotide Controlling Tumor Suppressor REST Is a Novel Therapeutic Medicine for Neuroendocrine CancerBy Noshin Noorjahan - July 2, 20240260Researchers investigated amido-bridged nucleic acid-based splice-switching oligonucleotides targeting RE1-silencing transcription factor (REST) splicing as a novel therapy.[Molecular Therapy – Nucleic Acids]Full ArticleGraphical Abstract